BUZZ-Clearside jumps as eye disease drug succeeds in mid-stage trial

Reuters10-09

** Shares of drug developer Clearside Biomedical rise ~38.5% to $2.05 premarket

** Company says its drug CLS-AX showed stable vision in patients with wet age-related macular degeneration for up to 6 months compared to Regeneron Pharmaceuticals' aflibercept, during a mid-stage trial

** Wet AMD is a disorder where abnormal blood vessels grow in the back of the eye, causing vision loss

** Up to last close, Clearside stock up 26.5% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment